Novo's Tresiba matches Sanofi rival Lantus in CV safety study—and cuts down the rate of severe hypoglycemia, too

12th June 2017 Uncategorised 0

Competing with Sanofi blockbuster Lantus is no easy task, but that’s exactly what Novo Nordisk’s long-acting insulin Tresiba has to do. Thanks to new data, though, the drugmaker can safely say its newcomer poses no increased heart risks—and it has some advantages over its rival, too.

More: Novo's Tresiba matches Sanofi rival Lantus in CV safety study—and cuts down the rate of severe hypoglycemia, too
Source: fierce